Applied DNA Sciences Inc., a leader in PCR-based DNA technologies, has announced that it has regained compliance with Nasdaq's continued listing requirements. As of July 2, 2025, the company received a compliance notice from The Nasdaq Stock Market LLC, confirming it meets the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Consequently, a previously scheduled hearing before the Nasdaq Hearings Panel on July 15, 2025, has been cancelled, and the company's securities will continue to be listed and traded on The Nasdaq Capital Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.